McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Feb. 17, 2012, McNeil Consumer Healthcare, a division of McNeil-PPC, a subsidiary of Johnson & Johnson, voluntarily recalled approximately 574,000 bottles of its over-the-counter pain reliever and fever-reducer Infants’ Tylenol Oral Suspension, 1 oz. Grape. The voluntary recall was initiated after consumers complained of having difficulty using the SimpleMeasure dosing system.

The SimpleMeasure dosing system used for Infants’ Tylenol includes a dosing syringe that is inserted into a flow restrictor at the top of the bottle to measure dosage. Complaints were received from some consumers that the flow restrictor was pushed into the bottle when the syringe was inserted.

McNeil states, in a press release, that the voluntary recall was at the wholesale and retail level for seven lots distributed nationwide in the United States and that no adverse events have been reported. McNeil states that consumers may continue to use the product “provided that the flow restrictor at the top of the bottle remains in place,” but cautions consumers to not use the product if the flow restrictor is pushed into the bottle.

The specific lot numbers recalled were BIL0U00, BIL0V00, BIL3500, BJL2D00, BJL2E00, BJL2T00, BJL2U00, UPC Code 300450122308. Consumers can request a refund from McNeil by visiting www.tylenol.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here